adrenomedullin and Migraine-without-Aura

To determine whether the IV infusion of adrenomedullin, a potent vasodilator belonging to calcitonin family of peptides, provokes attacks of migraine in patients.. Twenty patients with migraine without aura participated in a placebo-controlled and double-blind clinical study. In a randomized crossover design, the patients received an IV infusion of human adrenomedullin (19.9 pmol/kg/min) or placebo (saline) administrated via an automated IV pump (20 minutes). The patients participated in 2 study days with a washout period of minimum of 7 days. The primary outcome of the study was predefined as a difference in migraine incidence (0-12 hours), and the secondary outcomes were the area under curve (AUC. Eleven patients with migraine without aura (55%) fulfilled migraine attacks criteria after adrenomedullin infusion compared to only 3 patients who reported attack (15%) after placebo (. Our data implicate adrenomedullin in migraine pathogenesis. This suggests that adrenomedullin or its receptors are novel therapeutic targets for the treatment of migraine. However, we cannot discount the possibility that adrenomedullin may be acting through the canonical calcitonin gene-related peptide receptor.. ClinicalTrials.gov Identifier: NCT04111484.

Topics: Adrenomedullin; Adult; Arterial Pressure; Cross-Over Studies; Double-Blind Method; Female; Flushing; Headache; Heart Rate; Humans; Infusions, Intravenous; Male; Migraine without Aura; Pilot Projects; Random Allocation; Severity of Illness Index; Vasodilator Agents; Young Adult